Can I ask a question, has anyone had stage 1 breast cancer but grade 3 her2 positive? If so did you do chemotherapy...

Understanding Your Stage 1, Grade 3, HER2+ Breast Cancer Treatment Plan

I can see you're looking for patient experiences with a specific treatment pathway. While I can't connect you with other patients directly, I can help you understand what the medical evidence says about your situation and what questions to ask your care team about outcomes.

Let me break down what we know about your cancer type and treatment approach:

---

Your Cancer Type: Stage 1, Grade 3, HER2-Positive

What this means:

According to NCCN Guidelines, your cancer has some important characteristics:

• Stage 1 = Early-stage disease (tumor is relatively small, hasn't spread to lymph nodes or distant sites)
• Grade 3 = High-grade (cells look very abnormal under the microscope and tend to grow faster)
• HER2-positive = Your cancer cells have extra copies of the HER2 protein, which makes them grow faster BUT also makes them responsive to targeted therapy

The combination of early stage with high grade and HER2+ status is actually significant because HER2-targeted therapy is very effective for this subtype. As noted in NCCN Guidelines for Invasive Breast Cancer, HER2+ cancers are treated with targeted therapies that specifically block this protein.

---

Your Treatment Plan: Breaking It Down

Your treatment sequence appears to be:

1. Chemotherapy (before surgery) - called neoadjuvant therapy
2. Lumpectomy (surgery)
3. Radiation therapy
4. Ado-trastuzumab emtansine (Kadcyla) - 14 sessions

Why this sequence makes sense:

According to NCCN Guidelines, for HER2+ breast cancer:

"Chemotherapy with a HER2-targeted therapy is used to treat HER2+ cancer. Trastuzumab and pertuzumab are examples of HER2-targeted therapy."

Your upfront chemotherapy helps shrink the tumor before surgery, which is called preoperative (neoadjuvant) therapy. After surgery, additional HER2-targeted therapy continues to target any remaining cancer cells.

Kadcyla (ado-trastuzumab emtansine) specifically:

• This is an antibody-drug conjugate (ADC) that attaches directly to HER2 on cancer cells
• It delivers chemotherapy directly into HER2+ cancer cells
• NCCN Guidelines note that Kadcyla is used particularly when there is residual disease (cancer remaining) after initial treatment

---

What the Evidence Shows About Outcomes

Important context: I don't have access to specific patient outcome data or survival statistics in my knowledge base, but here's what the medical literature supports:

For HER2+ breast cancer with your treatment approach:

According to NCCN Guidelines for Invasive Breast Cancer, the standard approach for HER2+ disease includes:

• Chemotherapy combined with HER2-targeted therapy
• Continuation of HER2-targeted therapy for up to 1 year total
• Radiation therapy when appropriate (as in your plan)

The guidelines emphasize that HER2-targeted therapy has significantly improved outcomes for patients with HER2+ breast cancer compared to chemotherapy alone.

---

Questions to Ask Your Oncology Team About YOUR Specific Outcomes

Since you're asking about remission and what to expect, here are targeted questions:

1. "Based on my specific pathology results and response to the initial chemotherapy, what is my risk of recurrence?" (This helps you understand your individual prognosis)

2. "What does 'remission' mean in my case, and what will we be monitoring for after I complete Kadcyla?" (Different doctors use this term differently)

3. "After I finish the 14 sessions of Kadcyla, what is my follow-up plan?" (This includes imaging, blood work, and how often you'll be seen)

4. "Are there any biomarker tests (like Oncotype DX or similar) that could help predict my individual response to this treatment?" (Some patients find this helpful for understanding their specific risk)

5. "What symptoms should I report immediately, and what's the difference between expected side effects and something that needs urgent attention?"

6. "Will I need any additional endocrine therapy (hormone therapy) after HER2-targeted therapy is complete?" (This depends on whether your cancer is also hormone receptor-positive)

---

Finding Patient Support & Stories

While I can't connect you with specific patients, here are evidence-based resources:

• American Cancer Society (cancer.org) - has patient stories and support communities
• Breastcancer.org - extensive patient forums organized by cancer type
• NCCN Patient Guides (nccn.org/patientguidelines) - includes real patient perspectives
• Your hospital's patient navigator or social worker - can often connect you with support groups specific to HER2+ breast cancer

---

Key Takeaway

Your treatment plan aligns with NCCN Guidelines for HER2-positive breast cancer, which emphasizes the combination of chemotherapy, surgery, radiation, and extended HER2-targeted therapy. The fact that you're receiving this comprehensive approach reflects current best practices for your cancer subtype.

The most important conversation is with your medical oncologist about:

• How your tumor responded to the initial chemotherapy
• Your individual risk factors
• What remission and long-term monitoring will look like for YOU specifically

---

This information is for educational purposes only. Always consult your healthcare team for personalized medical advice and decisions.